List of Excipients in Branded Drug AZASITE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn	AZASITE	azithromycin monohydrate	17478-307	BENZALKONIUM CHLORIDE
Akorn	AZASITE	azithromycin monohydrate	17478-307	CITRIC ACID MONOHYDRATE
Akorn	AZASITE	azithromycin monohydrate	17478-307	EDETATE DISODIUM
Akorn	AZASITE	azithromycin monohydrate	17478-307	MANNITOL
Akorn	AZASITE	azithromycin monohydrate	17478-307	POLOXAMER 407
Akorn	AZASITE	azithromycin monohydrate	17478-307	POLYCARBOPHIL
Akorn	AZASITE	azithromycin monohydrate	17478-307	SODIUM CHLORIDE

AZASITE Excipient Strategy and Commercial Opportunities in Ophthalmic Azithromycin

Last updated: August 27, 2026

AZASITE is azithromycin ophthalmic solution 1%, an antibiotic product approved for bacterial conjunctivitis. Its commercial differentiation came primarily from the DuraSite bioadhesive vehicle, which uses polycarbophil to increase ocular residence time and support a twice-daily, two-day dosing regimen. The core opportunity has shifted from basic generic replication to differentiated ophthalmic delivery: preservative-free presentations, improved multidose packaging, longer shelf life, pediatric tolerability, and expanded ocular-surface applications.

The strongest excipient strategy is to preserve azithromycin’s antimicrobial performance while improving comfort, retention, manufacturability, and regulatory flexibility. A product that merely copies the active ingredient without matching the vehicle and device experience is vulnerable to substitution and limited pricing power.

What is AZASITE and how does its formulation work?

AZASITE contains azithromycin at a 1% concentration in an ophthalmic vehicle based on polycarbophil. The product is associated with the DuraSite delivery platform, a mucoadhesive vehicle designed to increase contact with the ocular surface.

Attribute	AZASITE
Active ingredient	Azithromycin
Strength	1% ophthalmic formulation
Dosage form	Topical ophthalmic solution/suspension-type viscous formulation
Approved indication	Bacterial conjunctivitis
Original sponsor	Inspire Pharmaceuticals
Current commercial ownership	Brand and generic ownership has changed through licensing, acquisition and commercialization arrangements
Dosing regimen	Twice daily for two days
Key excipient platform	Polycarbophil-based bioadhesive vehicle
Approval pathway	NDA 050793
Primary commercial advantage	Extended ocular residence and short treatment course

The approved labeling identifies polycarbophil, sodium phosphate monobasic monohydrate, sodium chloride, sodium hydroxide and purified water among the inactive ingredients. The formulation is adjusted for ophthalmic pH and osmotic compatibility.[1]

Polycarbophil is a cross-linked polyacrylic acid polymer. In ophthalmic products, it can hydrate and interact with mucin on the ocular surface. That interaction increases retention compared with a conventional low-viscosity aqueous solution. The vehicle can also make the product appear more viscous, which creates a tradeoff between retention and patient comfort.

What excipients protect the commercial performance of AZASITE?

The principal excipient-related value is not the presence of an individual inactive ingredient. It is the combination of polymer concentration, pH, osmolality, particle or droplet behavior, preservative system, container closure and delivery dose.

Polycarbophil

Polycarbophil is the core strategic excipient. It can support:

• Increased ocular-surface residence time.
• Reduced drainage through the nasolacrimal duct.
• A shorter dosing regimen.
• Greater differentiation from conventional azithromycin drops.
• Potentially lower dosing frequency in future products.

Polycarbophil concentration must be controlled tightly. Excessive viscosity can cause blurred vision, stinging, transient discomfort and inconsistent drop formation. Too little polymer can reduce retention and erase the product’s principal delivery advantage.

The polymer also creates manufacturing risks. Hydration time, mixing energy, order of addition, pH adjustment and shear exposure can affect viscosity and uniformity. A change in polymer grade may trigger comparative performance questions even if the finished product meets basic chemical specifications.

Buffer system

Sodium phosphate supports pH control. The formulation must balance three variables:

1. Azithromycin chemical stability.
2. Ocular comfort.
3. Polymer hydration and viscosity.

Phosphate concentration can affect ionic strength and the behavior of polycarbophil. A reformulator cannot assume that a buffer substitution, such as citrate or borate, will preserve the same rheology or ocular retention.

A lower-buffer-capacity formulation may improve comfort but can become more sensitive to manufacturing variation. A stronger buffer may improve pH control while increasing irritation risk or changing polymer behavior.

Sodium chloride

Sodium chloride supports osmolality. The target must remain sufficiently close to tear fluid to reduce burning and reflex tearing. Excessive tonicity can impair comfort, while a markedly hypotonic formulation can also be poorly tolerated.

A commercial development program should measure osmolality after sterilization, during stability storage and after container opening. Changes in water loss, evaporation or packaging permeability can materially alter the patient experience.

Sodium hydroxide

Sodium hydroxide is used primarily for pH adjustment. It is a process-critical excipient rather than a differentiation element. Its concentration should be controlled through a validated pH adjustment procedure because small changes can influence azithromycin stability, polymer ionization and viscosity.

Water quality

Water-for-injection or equivalent high-quality pharmaceutical water is necessary for a sterile ophthalmic product. Water quality affects microbial control, endotoxin risk, conductivity, pH and stability. A formulation with a polymeric vehicle can be more sensitive to trace contaminants than a simple aqueous solution.

What formulation patents protect AZASITE and the DuraSite strategy?

The historical intellectual-property value of AZASITE centered on the formulation and delivery platform rather than azithromycin itself. Azithromycin is a mature macrolide antibiotic with no meaningful composition-of-matter exclusivity remaining for this product.

The relevant patent categories include:

Patent category	Commercial purpose	Relevance to AZASITE
Mucoadhesive ophthalmic vehicle	Extends residence on the eye	Core DuraSite concept
Polycarbophil-containing formulation	Controls viscosity and retention	Supports formulation differentiation
Ophthalmic antibiotic delivery	Combines antimicrobial agent with vehicle	Product-specific protection
Container and dispensing system	Controls dose, sterility and stability	May support device differentiation
Method of treatment	Defines dosing and disease use	May create narrow method-of-use protection
Manufacturing process	Protects hydration, mixing or sterilization	Can increase development barriers

The historical U.S. DuraSite portfolio included patents assigned to or associated with Inspire Pharmaceuticals and related development entities. Key patent families covered bioadhesive ophthalmic compositions and polymer-containing drug delivery vehicles. Patent term for the earliest platform claims has generally expired or approached expiration, depending on the specific patent, filing date, patent-term adjustment and jurisdiction.

A current freedom-to-operate review must distinguish between:

• Expired platform patents.
• Continuations with different claim scope.
• Patent-term adjustments.
• Orange Book-listed patents.
• Non-Orange-Book process or device patents.
• Third-party patents covering sterile manufacture or packaging.

A formulation patent can remain commercially relevant even when it is not listed in the Orange Book. Such patents may affect development strategy, licensing and litigation risk without automatically blocking an ANDA.

What is the Orange Book status of AZASITE?

AZASITE was approved under NDA 050793 for bacterial conjunctivitis. The Orange Book is the controlling FDA reference for listed patents, therapeutic equivalence codes and approval status.[2]

The principal regulatory conclusions are:

• The active ingredient, azithromycin, is off-patent.
• The product’s original commercial differentiation depended on its delivery vehicle and dosing schedule.
• Any current patent analysis must be performed against the live Orange Book entry and the applicable patent family records.
• A listed patent does not establish that all formulation, device or manufacturing claims are enforceable.
• An unlisted patent can still be relevant to a 505(b)(2) product, licensing transaction or litigation strategy.

Generic applicants seeking approval of azithromycin ophthalmic products may use the ANDA pathway if they can demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. A materially different vehicle, preservative system or delivery device may move the product toward a 505(b)(2) strategy rather than a straightforward ANDA.

When does AZASITE lose exclusivity?

AZASITE’s regulatory exclusivity and patent protection are separate issues.

Protection type	AZASITE position
Azithromycin compound patent	Expired
Original NDA exclusivity	Expired
Pediatric exclusivity	Historical period, expired
Formulation-platform protection	Largely historical; status depends on individual patent claims
Orange Book-listed patent protection	Must be checked against the current FDA entry
Generic pathway	Available subject to FDA requirements and any enforceable patent barriers
Biosimilar pathway	Not applicable because azithromycin is a small-molecule drug

The main commercial barrier is no longer basic regulatory exclusivity. It is the ability to produce a sterile, stable and patient-acceptable product that matches the reference product’s performance without excessive cost.

Which companies are challenging AZASITE through generic competition?

Generic competition is likely to come from ophthalmic manufacturers with established sterile liquid or suspension capabilities, including companies active in abbreviated new drug applications and hospital or retail ophthalmics.

The competitive field can include:

• Large generic manufacturers with ophthalmic manufacturing sites.
• Specialty ophthalmology companies.
• Contract development and manufacturing organizations.
• Regional manufacturers seeking licensing rights.
• Reformulation companies pursuing 505(b)(2) approval.

The principal competitive distinction is between a low-cost copy and a differentiated alternative.

Product strategy	Regulatory route	Commercial position
Same active and substantially equivalent vehicle	ANDA	Lowest development risk; price competition
Preservative-free formulation	ANDA or 505(b)(2), depending on differences	Premium opportunity in sensitive-eye segments
New bioadhesive polymer	505(b)(2) likely	Stronger differentiation; higher development burden
Improved bottle or unit-dose device	ANDA or 505(b)(2)	Better usability and contamination control
Extended-release ocular formulation	505(b)(2) or new NDA	Potentially higher value; clinical evidence required
Combination antibiotic and anti-inflammatory	505(b)(2) or NDA	Larger development and safety burden

What excipient strategies create new commercial opportunities?

Preservative-free AZASITE

A preservative-free product could target patients with ocular-surface disease, contact-lens-associated sensitivity and repeated exposure to topical ophthalmic preservatives. The commercial value would depend on a multidose container that maintains sterility or a unit-dose format with acceptable cost.

Preservative-free packaging options include:

• Unit-dose polymer ampoules.
• One-way valves.
• Filtered multidose bottles.
• Airless dispensing systems.
• Preservative-free multidose systems with validated microbial protection.

A unit-dose product improves contamination control but increases packaging, filling and distribution costs. A multidose system supports retail convenience but creates more demanding container-closure and in-use stability requirements.

Lower-viscosity bioadhesive vehicle

The original DuraSite concept prioritizes retention. A next-generation formulation could target a lower viscosity while preserving mucoadhesion. This may reduce blur and improve patient acceptance.

Potential approaches include:

• Lower polycarbophil concentration.
• Alternative cross-linked acrylic polymers.
• Polymer blends with different hydration profiles.
• In situ gelling systems.
• Mucoadhesive polymers that respond to tear-fluid ions or pH.

Each approach requires comparative rheology, drop-size, spreading, ocular retention and tolerability studies. A polymer substitution is unlikely to be commercially meaningful without evidence that it preserves antimicrobial exposure and improves the patient experience.

Improved drop formation

Viscous ophthalmic products often have a higher risk of oversized drops or inconsistent dosing. An optimized formulation-device combination can reduce dose variability.

Relevant design targets include:

• Drop mass consistency.
• Lower squeeze force.
• Reduced residual volume.
• One-hand operation.
• Compatibility with elderly users.
• Reduced tip contamination.
• Consistent delivery across temperature conditions.

A device-based improvement can support premium positioning even when the formulation is chemically similar to the reference product.

Improved storage and distribution

If the reference product requires refrigerated storage or has restrictive in-use stability, an ambient-stable version could create a material commercial advantage. The development program would need to control:

• Polymer viscosity drift.
• Azithromycin degradation.
• Microbial stability after opening.
• Container permeability.
• Freeze-thaw performance.
• Light exposure.
• Shipping excursions.

Shelf-life extension is especially valuable for wholesalers, retail pharmacies and international markets where cold-chain infrastructure increases cost.

What FDA pathway applies to new AZASITE formulations?

ANDA pathway

An ANDA is most suitable when the proposed product matches the reference product in active ingredient, dosage form, strength, route and relevant formulation characteristics. The applicant must establish pharmaceutical equivalence and bioequivalence under FDA requirements.[3]

A generic applicant should expect scrutiny of:

• Azithromycin assay and impurities.
• Sterility.
• pH and osmolality.
• Viscosity and rheology.
• Particle size or dispersion behavior.
• Drop size and delivered volume.
• Preservative content, if applicable.
• Container-closure integrity.
• In-use stability.

505(b)(2) pathway

A 505(b)(2) application is more appropriate when the product changes the vehicle, preservative system, delivery mechanism, dosage regimen or clinical positioning in a way that cannot be fully supported by an ANDA reference to AZASITE.

Potential 505(b)(2) opportunities include:

• Preservative-free multidose delivery.
• Longer ocular residence.
• Reduced dosing frequency.
• New polymer systems.
• New indication supported by clinical data.
• Combination therapy.
• Improved pediatric administration.

The regulatory advantage is the ability to rely partly on existing azithromycin safety and efficacy data. The cost is the need to establish the consequences of the formulation or device changes.

What generic launch risks exist for AZASITE?

The principal generic launch risks are technical rather than compound-patent related.

Formulation equivalence risk

A generic that uses a conventional aqueous vehicle may not reproduce the reference product’s viscosity, retention or dosing experience. Even if the active ingredient concentration is correct, differences in vehicle performance can create regulatory questions.

Sterility and microbial risk

Polymeric formulations can complicate sterilization and microbial control. Terminal sterilization may be unsuitable for some formulations, forcing aseptic processing. Aseptic manufacturing increases capital and quality-system requirements.

Drop-size risk

Differences in nozzle geometry, viscosity and surface tension can change the delivered dose. This matters in ophthalmics because a larger drop can increase overflow, systemic absorption through the nasolacrimal pathway and patient discomfort.

Supply-chain risk

Polycarbophil and specialized ophthalmic packaging may have fewer qualified suppliers than standard excipients. A single-source polymer or device can create continuity risk.

Litigation risk

A Paragraph IV certification may be relevant if a generic applicant identifies an unexpired Orange Book-listed patent. The applicant may challenge patent validity, enforceability or infringement. Litigation timing depends on the patent listing, notice date and the filing of an infringement action. Historical platform patents should not be assumed to block a current launch without a claim-by-claim review.

What licensing deals and manufacturing partnerships matter?

Commercial opportunities exist at three levels:

1. Licensing of the bioadhesive formulation platform.
2. Contract manufacturing of sterile ophthalmic products.
3. Co-development of a preservative-free device and formulation.

The most valuable licensing assets are likely to be:

• Valid composition or formulation claims.
• Proprietary polymer grades.
• Comparative ocular-retention data.
• A validated multidose preservative-free container.
• Manufacturing know-how for sterile viscous suspensions.
• International regulatory packages.

A formulation company with only an excipient concept may have limited negotiating leverage. A stronger asset combines patent claims, stability data, scalable manufacturing and an FDA-compatible regulatory pathway.

How strong is the AZASITE patent estate?

The original AZASITE estate is strongest historically in formulation and delivery, not in the azithromycin molecule. Its present strength depends on whether any relevant claims remain unexpired, whether they are listed in the Orange Book and whether a proposed competitor practices the claimed limitations.

Estate component	Relative strength
Azithromycin composition of matter	Very weak; expired
Original use for bacterial conjunctivitis	Weak after historical exclusivity
Polycarbophil delivery platform	Historically meaningful; current value depends on surviving claims
Specific AZASITE formulation	Potentially relevant only if unexpired claims remain
Device and packaging	Potentially useful for differentiated products
Manufacturing know-how	Can remain commercially important without patent exclusivity
New preservative-free formulation	Strongest opportunity for new protection

New intellectual property should focus on narrow, measurable technical advantages. Stronger claim targets include polymer concentration ranges, viscosity windows, pH and osmolality combinations, drop-size performance, preservative-free microbial control and stability under defined conditions.

What revenue exposure and market opportunities exist?

AZASITE’s revenue exposure is concentrated in the ophthalmic anti-infective market, particularly bacterial conjunctivitis. The original short-course regimen can support adherence and lower patient burden, but generic entry places pressure on net price and formulary access.

Commercial opportunities are more defensible in segments where vehicle performance matters:

• Preservative-sensitive patients.
• Pediatric ophthalmology.
• Ocular-surface disease.
• Post-procedural care, subject to approved labeling.
• Retail products requiring simple administration.
• International markets with limited access to differentiated ophthalmic antibiotics.
• Combination or extended-residence products.

The highest-value strategy is likely a portfolio rather than a single product:

Portfolio product	Target customer	Value proposition
Low-cost generic	Payers and retail pharmacies	Price and availability
Preservative-free unit dose	Sensitive-eye patients	Tolerability and contamination control
Preservative-free multidose	Retail and specialty ophthalmology	Convenience with premium pricing
Low-blur bioadhesive version	Patients and prescribers	Retention with improved comfort
Device-enhanced version	Elderly and pediatric users	Easier, more consistent dosing
New polymer platform	Licensing partners	Broader ophthalmic pipeline value

Key Takeaways

• AZASITE’s commercial identity is tied to its polycarbophil-based DuraSite vehicle and short dosing regimen.
• Azithromycin itself provides little current patent protection.
• The strongest formulation opportunities are preservative-free delivery, lower-viscosity bioadhesion, improved drop formation and ambient stability.
• ANDA competition is feasible for close copies, while materially different vehicles or devices may require a 505(b)(2) strategy.
• Generic launch risk centers on formulation equivalence, sterility, rheology, drop size, packaging and manufacturing scale.
• New patent value is more likely to arise from formulation-device combinations and manufacturing controls than from azithromycin composition claims.
• A commercial portfolio should separate low-cost generic supply from premium preservative-free and device-enabled products.
• Current Orange Book listings, patent-term calculations and Paragraph IV exposure must be verified at the time of filing or transaction.

FAQs

Can polycarbophil be replaced in an AZASITE generic?

Yes, but replacing polycarbophil can create regulatory and performance differences. The applicant must establish that the alternative vehicle does not materially change viscosity, drop size, ocular retention, tolerability or product performance.

Is preservative-free azithromycin ophthalmic solution commercially attractive?

Yes. A preservative-free product could target patients with ocular-surface sensitivity and repeated exposure to preserved drops. Its success depends on packaging cost, microbial control, shelf life and reimbursement.

Does AZASITE qualify for biosimilar competition?

No. AZASITE contains azithromycin, a small-molecule drug. Competition proceeds through the generic drug framework, primarily an ANDA, or through a 505(b)(2) application for material formulation or delivery changes.

Can a new AZASITE formulation obtain patent protection?

Yes. Patent protection may be available for a novel and non-obvious polymer system, preservative-free container, viscosity range, stability profile, dosing regimen or formulation-device combination. The claims must provide measurable technical distinctions over prior art.

What is the most defensible commercial position for a new AZASITE product?

A preservative-free, low-blur, bioadhesive formulation in a validated multidose container offers the clearest differentiation. It combines excipient innovation, device value and patient-convenience benefits rather than competing solely on azithromycin price.

References

1. U.S. Food and Drug Administration. (2007). AzaSite (azithromycin ophthalmic solution) prescribing information. NDA 050793. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant or animal origin. https://www.fda.gov
4. U.S. Food and Drug Administration. (1999). Guidance for industry: Applications covered by section 505(b)(2). https://www.fda.gov
5. United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov
6. Inspire Pharmaceuticals, Inc. (2007). AzaSite product information and ophthalmic delivery technology materials. Corporate regulatory and product literature.